Inclusion Criteria:

          -  At any time prior to enrollment subjects must have IgG, IgA, kappa, or lambda
             monoclonal gammopathy confirmed in at least two assessments at least three months
             apart or histologically confirmed multiple myeloma or carry a diagnosis of smoldering
             myeloma based on prior documentation of serum m-spike (IgG or IgA) of at least 3g/dL
             serum m-spike (IgG or IgA) or 24h urine m-spike of at least 500mg/24h.

          -  Within 28 days prior to enrollment persistence of the clonal plasma cell disorder must
             be documented by presence of a clonal band on immunofixation of blood or urine or an
             abnormal serum free kappa/lambda ratio.

          -  Subjects with myeloma related organ dysfunction must have received prior therapy,
             reached at least partial remission with at least one of any number of prior regimens,
             and be candidates for observation off myeloma therapy based on lack of progression at
             least stable disease for at least 90 days prior to at study entry.

          -  Performance status ECOG performance status ≤ 2.

          -  Subjects must have laboratory test results within the following ranges:

               -  Hemoglobin ≥ 9.0 g/dl

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelet count ≥ 100,000/mcL

               -  Total bilirubin < 2.5 x institutional upper limit of normal

               -  AST (SGOT) ≤ 2.5 X institutional upper limit of normal

               -  ALT (SGPT) ≤ 2.5 X institutional upper limit of normal

               -  Calculated creatinine clearance (Cockcroft-Gault) ≥ 30ml/min

          -  Anti-myeloma treatment with proteasome inhibitors, IMiDsTM, corticosteroids, low dose
             cyclophosphamide (≤ 50mg per day) must have been discontinued at least 14 days prior
             to study entry. Conventional chemotherapy at conventional doses including
             cyclophosphamide at > 50mg per day must have been discontinued at least 28 days prior
             to study entry. At least 180 days must have passed since high dose chemotherapy used
             in the context of autologous stem cell transplantation. Prior radiation must have been
             completed at least 14 days prior to enrollment.

          -  Subjects must have the ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          -  Subjects receiving any other investigational agents.

          -  Concurrent use of any plasma cell directed therapy including corticosteroids (use of
             bisphosphonates is allowed).

          -  Subjects who have previously received an allogeneic stem cell transplant.

          -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection (including active HIV or hepatitis), symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements.

          -  Women with childbearing potential (last menstrual period within less than 24 months
             unless hysterectomy or bilateral oophorectomy has been performed since) as well as
             pregnant women are excluded from this study because DKK1 is expressed in placental
             tissue and a DKK1 immune response could harm the child. Breastfeeding women are
             excluded from this study because antibodies made in response to the dendritic cell
             DKK1 vaccine could enter milk and affect the health of the breastfed child.